---
title: "Tigermed Proposes New Three-Year Board Line-Up to Maintain Strategic Continuity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280993458.md"
description: "Tigermed Proposes New Three-Year Board Line-Up to Maintain Strategic Continuity"
datetime: "2026-03-30T09:50:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280993458.md)
  - [en](https://longbridge.com/en/news/280993458.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280993458.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280993458.md) | [繁體中文](https://longbridge.com/zh-HK/news/280993458.md)


# Tigermed Proposes New Three-Year Board Line-Up to Maintain Strategic Continuity

Tigermed Proposes New Three-Year Board Line-Up to Maintain Strategic Continuity

### Related Stocks

- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md)
- [TIGERMED (03347.HK)](https://longbridge.com/en/quote/03347.HK.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md)
- [Tigermed (300347.CN)](https://longbridge.com/en/quote/300347.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md)

## Related News & Research

- [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/en/news/280923090.md)
- [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/en/news/281644038.md)
- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/en/news/281231901.md)
- [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/en/news/281458440.md)
- [Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation](https://longbridge.com/en/news/280992698.md)